HIV

Nneka Mobisson of mDoc Healthcare in Nigeria will integrate ChatGPT-4 into their chatbot, Kem, which provides virtual self-care coaching for low-income women of reproductive age in Nigeria, to improve its accuracy and capacity to respond to queries with evidence-based information. The burden of maternal deaths in Nigeria remains inequitably high with many risks encountered even before conception, highlighting the importance of supporting self-care.

Zaza Ndhlovu of the Africa Health Research Institute in South Africa and Fekadu Tafesse of Oregon Health & Science University (OHSU) will identify the molecular mechanisms enabling HIV to survive in humans to help develop new therapies to fully eradicate the disease. Potent antiretroviral therapies have rendered HIV a manageable chronic disease, but it is still incurable. Needing daily medication over a lifetime makes this approach ultimately expensive and also challenging to maintain in low-resource settings.

Pratap Mukhopadhyaya from Wobble Base Bioresearch Pvt. Ltd. in India will develop a glucometer to detect HIV RNA. The existing major methodologies for viral load quantitation require sophisticated infrastructure and reagents that generate high priced tests (>50 USD per test) that are often not feasible for use in resource limited settings. The new assay involves making an HIV cDNA-DNA-invertase complex, which is added to sucrose solution to generate glucose through hydrolysis by the invertase enzyme that is detected using the glucometer.

ChipCare Corporation's mission is to unlock global health equity through point-of-care innovation. Our low-cost, handheld extremely mobile and rapid blood testing device will increase life-saving clinical decision making at the community level in poor or remote settings. By 2015, UN plans to have trained one million community health workers in Africa. Our goal is to have our device into the hands of every one of these community health workers.

Lu Lu of Shanghai Medical College, Fudan University in China working with Ling Ye of Emory University in the U.S., will design a potent HIV vaccine using selected sequences of one of the virus's envelope proteins to trigger the production of broadly neutralizing antibodies. This has been problematic due to the diversity of the viral envelope glycoprotein and its glycosylation shield, which prevent the immune system from recognizing it.

Linqi Zhang of Tsinghua University in China, working with Tongqing Zhou of the National Institutes of Health in the U.S., will design a broadly protective vaccine against HIV-1 derived from the atomic structure of the viral envelope protein from the dominant transmitted founder HIV-1 strain isolated from a high-risk population in China. HIV is a rapidly evolving virus that continually alters its structure to elude the immune system and antiretroviral drugs. This makes it challenging to develop an effective vaccine.

Ling Ye of Emory University in the U.S., working with Lu Lu of Shanghai Medical College, Fudan University in China, will design a potent HIV vaccine using selected sequences of one of the virus's envelope proteins to trigger the production of broadly neutralizing antibodies. This has been problematic due to the diversity of the viral envelope glycoprotein and its glycosylation shield which prevent the immune system from recognizing it.

Tongqing Zhou of the National Institutes of Health in the U.S., working with Linqi Zhang of Tsinghua University in China, will design a broadly protective vaccine against HIV-1 derived from the atomic structure of the viral envelope protein from the dominant transmitted founder HIV-1 strain isolated from a high-risk population in China. HIV is a rapidly evolving virus that continually alters its structure to elude the immune system and antiretroviral drugs. This makes it challenging to develop an effective vaccine.

Development of portable instrument for low income group countries which will be cost effective, time effective and highly efficient.

We propose the use of a diagnostic technology for TB and HIV based in the use of a chimeric recombinant antibody obtained from a marine organism and modified by genetic engineering, which when added to a sample of blood from a patient infected by a certain disease will produce a visual reaction in the sample allowing the user to do a simple and fast screening of infected patients. This process does not require any kind of equipment and the user can use the test even without previous training.